CoLucid Pharmaceuticals Inc. (CLCD) Reaches New 12-Month High at $10.83
CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) reached a new 52-week high during trading on Tuesday . The stock traded as high as $10.83 and last traded at $10.15, with a volume of 83,774 shares trading hands. The stock had previously closed at $9.49.
Separately, Zacks Investment Research lowered shares of CoLucid Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, June 29th.
The firm has a 50-day moving average of $8.80 and a 200-day moving average of $7.20. The firm’s market capitalization is $157.08 million.
CoLucid Pharmaceuticals (NASDAQ:CLCD) last issued its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.22. Analysts anticipate that CoLucid Pharmaceuticals Inc. will post ($4.01) earnings per share for the current fiscal year.
In related news, major shareholder Domain Partners Vi, L.P. sold 153,028 shares of CoLucid Pharmaceuticals stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $8.45, for a total transaction of $1,293,086.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.